Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Borderline Resectable Pancreatic Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Ended earlyNCT01359007
What this trial is testing

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Who this might be right for
Adenocarcinoma of Pancreas
University of Oklahoma 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04539808
What this trial is testing

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Who this might be right for
Pancreatic AdenocarcinomaStage 0 Pancreatic Cancer American Joint Committee on Cancer v8Stage I Pancreatic Cancer American Joint Committee on Cancer v8+2 more
OHSU Knight Cancer Institute
Early research (Phase 1)Study completedNCT01294358
What this trial is testing

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

Who this might be right for
Histologically or Cytologically Confirmed Pancreatic CaUnresectable or Borderline Resectable Pancreatic Ca
National Cancer Institute (NCI) 7
Early research (Phase 1)Ended earlyNCT01739439
What this trial is testing

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Who this might be right for
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasStage IIB Pancreatic Cancer+1 more
Fox Chase Cancer Center 6
Large-scale testing (Phase 3)Ended earlyNCT01836432
What this trial is testing

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreatic Carcinoma Non-resectableLocally Advanced Malignant Neoplasm
NewLink Genetics Corporation 302
Testing effectiveness (Phase 2)Ended earlyNCT04327986
What this trial is testing

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Who this might be right for
Histologically or Cytologically Confirmed Pancreatic CancerUnresectable or Borderline Resectable Pancreatic CancerPancreatic Neoplasms+2 more
National Cancer Institute (NCI) 3
Early research (Phase 1)Active Not RecruitingNCT04106856
What this trial is testing

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer (SHAPER)

Who this might be right for
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaLocally Advanced Unresectable Pancreatic Adenocarcinoma+4 more
University of Utah 22
Not applicableStudy completedNCT02780648
What this trial is testing

Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region

Who this might be right for
Pancreatic Neoplasms
Indiana University 36
Testing effectiveness (Phase 2)Looking for participantsNCT02598349
What this trial is testing

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

Who this might be right for
Pancreatic Cancer
Proton Collaborative Group 60
Testing effectiveness (Phase 2)Ended earlyNCT04698915
What this trial is testing

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Who this might be right for
SBRTBorderline Resectable Pancreatic CancerUnresectable Pancreatic Cancer
Galera Therapeutics, Inc. 177
42